

Healthy People 2010 Operational Definition

17-5. Increase the proportion of patient who receive verbal counseling from prescribers and pharmacists on the appropriate use and potential risks of medications.

17-5a. Prescribers.

National Data Source	National Survey of Prescription Medicine Information Received by Consumers, Food and Drug Administration (FDA).
State Data Source	Not identified.
Healthy People 2000 Objective	Objective 12.8 (Food and Drug Safety).
Changes since the 2000 Publication	None.
Measure	Percent
Baseline (Year)	24 (1998)
Target	95
Target-Setting Method	296 percent improvement. For a discussion of target-setting methods, see Part A, section 4.
Numerator	Number of persons who received verbal counseling from the prescriber on the appropriate use and potential risks of medication prescribed.
Denominator	Number of persons aged 18 years and older who received a new prescription for themselves or a household member in the four weeks prior to the survey administration.
Population targeted	U.S civilian, noninstitutionalized population.
Questions Used To Obtain the National Baseline Data	From the 1998 National Survey of Prescription Medicine Information Received by Consumers: ➤ [At the doctor's office] Did you talk about: <ul style="list-style-type: none">○ How much of the medicine to take or use?○ How often to take or use the medicine?

- *Any precautions to take while using the medicine?*
- *Any possible side effects?*

Expected Periodicity

Periodic

Comments

A person is considered to have received counseling on medication use and risks if he or she answered “yes” to any of the questions listed above.

Objective 17-5 is adapted from a measure in Healthy People 2000 objective 12.8 (Food and Drug Safety), which tracked the proportion of people who receive useful information verbally and in writing for new prescriptions from prescribers or dispensers. Objective 17-5 tracks the proportion of patients receiving verbal counseling at the doctor’s office (17-5a) or pharmacies (17-5b) on appropriate use and potential risks of prescription medications.

See Appendix A for focus area contact information.